What laboratory tests should be ordered for a child of a parent with protein C deficiency to assess their coagulation profile?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Laboratory Testing for Children of Parents with Protein C Deficiency

Order a protein C activity assay (chromogenic or clot-based method) as the primary screening test for the child, ideally after 6 months of age to avoid physiologically low neonatal levels. 1, 2

Primary Testing Approach

Initial Screening Test

  • Protein C activity assay is the recommended first-line test, using either chromogenic or clot-based (coagulometric) methods 1, 2
  • The chromogenic assay is most commonly used and detects the majority of protein C deficiencies 2
  • Consider adding a coagulometric assay if chromogenic results are normal but clinical suspicion remains high, as rare qualitative defects may be missed by chromogenic methods alone 2

Optimal Timing for Testing

  • Test after 6 months of age when possible, as protein C levels are physiologically low in neonates and gradually increase to adult levels 1
  • If testing must be done earlier due to clinical concerns, interpret results cautiously and plan for repeat testing after 6 months 1
  • Avoid testing during acute illness, as protein C is an acute phase reactant and levels can be transiently reduced 1

Sample Collection Requirements

Proper Specimen Handling

  • Collect venous blood into 3.2% (0.105-0.109 mol/L) trisodium citrate at a 1:10 ratio 3
  • Double-centrifuge to obtain platelet-poor plasma with residual platelet count <10.0 × 10⁹/L 3
  • Test within 4 hours of collection, or freeze at -20°C for ≤2 weeks or -70°C for >2 weeks 3
  • Rapidly thaw frozen samples in a 37°C waterbath and mix thoroughly before testing 3

Interpretation of Results

Expected Findings in Heterozygous Deficiency

  • Heterozygous protein C deficiency typically shows levels between 35% and 65% of normal, while normal individuals have levels between 70% and 130% 4
  • Both parents should be tested to confirm hereditary transmission if the child shows deficiency 5

Type Classification

  • Type I deficiency: Both functional (activity) and antigenic (immunological) levels are reduced proportionally 4
  • Type II deficiency: Antigenic levels are normal but functional activity is reduced (qualitative defect) 4
  • Differentiation requires both functional and antigenic assays 4

Additional Considerations

Baseline Coagulation Screening

  • Preliminary coagulation screening (PT/aPTT) is useful to detect previously unknown factor deficiencies that could interfere with protein C testing 6
  • These routine tests will be normal in isolated protein C deficiency 1

Genetic Testing

  • Genetic analysis of the PROC gene (chromosome 2q14.3) allows definitive diagnosis and confirms inherited versus acquired deficiency 1, 2
  • Genetic testing is particularly valuable in families with severe protein C deficiency and can identify asymptomatic carriers 2
  • Consider genetic testing if functional assays show deficiency, especially for family planning and counseling purposes 2

Critical Pitfalls to Avoid

Timing and Clinical Context

  • Do not test during acute thrombotic events, as protein C levels may be consumed and falsely low 1
  • Do not test while on anticoagulation (warfarin reduces protein C levels; heparin may interfere with assays) 1
  • Do not rely solely on neonatal testing, as physiologically low levels in infants can lead to false-positive results 1

Assay Limitations

  • Be aware that chromogenic assays may miss rare qualitative defects (Type II deficiency) that would be detected by coagulometric methods 2
  • Icterus, hemolysis, and lipemia can interfere with coagulation assays, so ensure proper sample quality 3

Clinical Implications

  • Asymptomatic heterozygous deficiency is common and does not automatically require prophylactic anticoagulation 4, 7
  • Homozygous deficiency (extremely rare) presents in the neonatal period with purpura fulminans and requires immediate intervention 5
  • Variable penetrance means not all individuals with protein C deficiency will develop thrombosis, even with very low levels 7

References

Research

Protein C Deficiency.

Archives of pathology & laboratory medicine, 2019

Research

The phenotypic and genetic assessment of protein C deficiency.

International journal of laboratory hematology, 2012

Guideline

Testing for Factor V Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Hereditary protein C deficiency: a review of the genetics, clinical presentation, diagnosis and treatment.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1990

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Asymptomatic homozygous protein C deficiency.

Acta haematologica, 1990

Related Questions

At what percentage activity of Protein C (PC) is a deficiency diagnosed?
Does a patient with a family history of protein C deficiency and no symptoms require a repeat screening test?
What is the management of protein C deficiency?
Is Protein C deficiency an autosomal recessive disorder?
What is the management plan for a 22-year-old patient with protein C deficiency, elevated D-dimer (elevated fibrin degradation products), and a family history of deep vein thrombosis (DVT) in a relative with protein C deficiency?
How to manage reverse trigger in patient-ventilator asynchrony, particularly in patients with underlying respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD) or Acute Respiratory Distress Syndrome (ARDS)?
What are the recommended next steps for a patient with a history of heavy cannabis use, now abstinent for 4 weeks?
What does a vitamin D level of 22 ng/mL indicate and how should it be treated in an adult patient?
Is it acceptable to continue and cautiously uptitrate GLP-1RA (Glucagon-like peptide-1 receptor agonist), such as semaglutide (semaglutide), in a 50-year-old male patient with type 2 diabetes mellitus, hypertension, obesity (BMI 36.4 kg/m²), non-alcoholic steatohepatitis (MASLD), obstructive sleep apnea, chronic ethanol abuse, and diabetic kidney disease, who has moderate non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema, and is already on telmisartan, SGLT2 (Sodium-glucose cotransporter 2) inhibitor, and finerenone, with structured retinal monitoring?
Is it acceptable to continue and cautiously uptitrate GLP-1RA (Glucagon-like peptide-1 receptor agonist), such as semaglutide (semaglutide), in a 50-year-old male patient with type 2 diabetes mellitus, hypertension, obesity (BMI 36.4 kg/m²), non-alcoholic steatohepatitis (MASLD), obstructive sleep apnea, chronic ethanol abuse, and diabetic kidney disease, who has moderate non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema, and is already on telmisartan, SGLT2 (Sodium-glucose cotransporter 2) inhibitor, and finerenone, with structured retinal monitoring?
What are the guidelines for using Dextromethorphan (cough suppressant) in a typical adult patient with a cough, considering potential interactions and medical history, including respiratory conditions such as asthma or Chronic Obstructive Pulmonary Disease (COPD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.